Evaluation of exenatide vs. insulin glargine in type 2 diabetes: Cost-effectiveness analysis in the German setting

Diabetes, Obesity and Metabolism

Volumn 11, Issue 11, 2009, Pages 1068-1079

  Mittendorf, T ^a   Smith Palmer, J ^a   Timlin, L ^c   Happich, M ^d   Goodall, G ^b  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^b IQVIA   (United States)

^c European Health Outcomes Research   (United Kingdom)

^d LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Cost effectiveness; Exenatide; Insulin glargine; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLUCOSE; INSULIN GLARGINE;

ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; GERMANY; GLYCEMIC CONTROL; HEALTH INSURANCE; HUMAN; HYPOGLYCEMIA; LIFE EXPECTANCY; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; TREATMENT OUTCOME; WEIGHT CHANGE;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DRUG COSTS; FEMALE; GERMANY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PEPTIDES; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOMS;

EID: 70350165090     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01099.x     Document Type: Article

References (54)

1. Hauner H, Koster I, von Ferber L. Prevalence of diabetes mellitus in Germany 1998-2001. Secondary data analysis of a health insurance sample of the AOK in Hessen. Dtsch Med Wochenschr 2003, 128:2632-2637.
2. Stock SA, Redaelli M, Wendland G, Civello D, Lauterbach KW. Diabetes-prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany. Diabet Med 2006, 23:299-305.
3. http://www.who.int/diabetes/commoncondition/en/, World Health Organization. Diabetes is a common condition and its frequence is dramatically rising all over the world. Available at:, Accessed August 2008
4. Jonsson B. Revealing the cost of type II diabetes in Europe. Diabetologia 2002, 45:S5-S12.
5. Wagenpfeil S, Neiss A, Goertz A. Bootstrap confidence intervals for costs-of-illness of type 2 diabetes mellitus in Germany. Value Health 2002, 5:397-403.
6. Rathmann W, Haastert B, Icks A, Giani G. Trends in outpatient prescription drug costs in diabetic patients in Germany, 1994-2004. Diabetes Care 2007, 30:848-853.
7. http://www.gbe-bund.de/gbe10/pkg_isgbe5.prc_isgbe?p_uid=gast&p_aid=7 7807995&p_sprache=E, Federal Health Monitoring. Available at:, Accessed August 2008
8. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591.
9. Gaede P, Pedersen O. Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. Diabetes 2004, 53(Suppl. 3):S39-S47.
10. Goldstein BJ, Gomis R, Lee HK, Leiter LA. Type 2 diabetes-treat early, treat intensively. Int J Clin Pract Suppl 2007, 61:16-21.
11. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992, 267:7402-7405.
12. Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 2002, 87:1282-1290.
13. Parkes DG, Pittner R, Jodka C, Smith P, Young A. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Metabolism 2001, 50:583-589.
14. Kolterman OG, Buse JB, Fineman MS. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003, 88:3082-3089.
15. Kolterman OG, Kim DD, Shen L. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005, 62:173-181.
16. Nielsen LL, Baron AD. Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opin Investig Drugs 2003, 4:401-405.
17. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2628-2635.
18. Glass LC, Qu Y, Lenox S. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. Curr Med Res Opin 2008, 24:639-644.
19. Gedulin BR, Nikoulina SE, Smith PA. Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 2005, 146:2069-2076.
20. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004, 117:77-88.
21. Ferdaoussi M, Abdelli S, Yang JY. Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway. Diabetes 2008, 57:1205-1215.
22. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559-569.
23. Palmer AJ, Roze S, Valentine W. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004, 20:S27-S40.
24. Graf von der Schulenburg JM, Greiner W, Jost F. German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health 2008, 11:539-544.
25. Ray JA, Valentine WJ, Secnik K. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin 2005, 21:1617-1629.
26. Koster I, von Ferber L, Ihle P, Schubert I, Hauner H. The cost burden of diabetes mellitus: the evidence from Germany-the CoDiM Study. Diabetologia 2006, 49:1498-1504.
27. Koster I, Hauner H, von Ferber L. Heterogenit ät der Kosten bei Patienten mit Diabetes mellitus: Die KoDiM-Studie [Heterogeneity of costs of diabetic patients: the Cost of Diabetes Mellitus Study. Dtsch Med Wochenschr 2006, 131:804-810.
28. von Ferber L, Koster I, Hauner H. Medical costs of diabetic complications total costs and excess costs by age and type of treatment results of the German CoDiM Study. Exp Clin Endocrinol Diabetes 2007, 115:97-104.
29. Kolominsky-Rabas PL, Heuschmann PU, Marschall D. Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke 2006, 37:1179-1183.
30. 2007, DRG prices in Germany
31. Kulp W, Garrido Velasco M, Greiner W, Graf von der Schulenburg JM. The Use of the Excimer Laser in Refractive Surgery 2003, Baden-Baden, Nomos Verlagsgesellschaft
32. 2008, http://www.whocc.no/atcddd/indexdatabase/, WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index, Available at:, Accessed August 2008
33. Yurgin NR, Secnik K, Cottrell S. Blood glucose monitoring recommendations and practices in patients with type 2 diabetes: a survey of healthcare professionals and patients in the UK. Value Health 2006, 9:A37.
34. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002, 22:340-349.
35. http://www.aihw.gov.au/publications/health/bdia/bdia-x05.pdf, The Burden of Disease and Injury in Australia. Australian Institute of Health and Welfare. Available at:
36. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000, 38:583-637.
37. Matza L, Boye KS, Yurgin N, Brewster-Jordan J, Mannix S, Shorr JM, Barber BL. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res 2007, 16:1251-65.
38. Ray JA, Boye KS, Yurgin NR. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. Curr Med Res Opin 2007, 23:609-622.
39. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005, 14:217-230.
40. Henry RR, Ratner RE, Stonehouse AH. Exenatide maintained glycemic control with associated weight reduction over 2 years in patients with type 2 diabetes (abstract 485-P). Diabetes 2006, 55(Suppl. 1):A116.
41. Heller S. Weight gain during insulin therapy in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2004, 65(Suppl. 1):S23-S27.
42. Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol 2003, 2:33-47.
43. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995, 44:1249-1258. UKPDS Group U.K.
44. Liebl A, Breitscheidel L, Nicolay C, Happich M. Direct costs and health-related resource utilisation in the 6 months after insulin initiation in German patients with type 2 diabetes mellitus in 2006: INSTIGATE study. Curr Med Res Opin 2008, 24:2349-2358.
45. Mack CM, Moore CX, Jodka CM. Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures. Int J Obes (Lond) 2006, 30:1332-1340.
46. Veldhorst M, Smeets A, Soenen S. Protein-induced satiety: effects and mechanisms of different proteins. Physiol Behav 2008, 94:300-307.
47. Klonoff DC, Buse JB, Nielsen LL. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008, 24:275-286.
48. Dennett SL, Boye KS, Yurgin NR. The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literature. Value Health 2008, 11:478-486.
49. Bunck MC, Diamant M, Corner A. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009, 32:762-768.
50. Gerstein HC, Rosenstock J. Insulin therapy in people who have dysglycemia and type 2 diabetes mellitus: can it offer both cardiovascular protection and beta-cell preservation?. Endocrinol Metab Clin North Am 2005, 34:137-154.
51. 2008, http://www.who.int/choice/costs/CER_levels/en/index.html, World Health Organization. Threshold values for intervention cost-effectiveness by Region. Choosing Interventions that are Cost Effective (WHO-CHOICE). Available at:, Accessed August
52. 2009, http://www.scottishmedicines.org.uk/smc/5206.html, Scottish Medicines Consortium. Exenatide 5 or 10 micrograms solution for injection, prefilled pen. (376/07). Available at:, Accessed July
53. 2009, www.wido.de/arzneiverordungs-rep.html, Arzneiverordnungsreport 2007. Available at:, Accessed July
54. 2009, www.kbv.de/ebm2008/ebmgesamt.htm, Kassenärztliche Bundesvereinigung Berlin, Einheitlicher Bewertungsmassstab fürärztliche Leistungen 4/2008. Available at:, Accessed July